HPV Vaccination in New Jersey
Rula Btoush, PhD, RN
Associate Professor
Rutgers School of Nursing


HPV Vaccine Uptake in New Jersey
Based on information reported to NJIIS on 11-19 year old adolescents
Rula Btoush, PhD, RN; Associate Professor; Rutgers School of Nursing
Dennis P. Carmody, PhD; Professor Emeritus; Rutgers School of Nursing
Jennifer Tsui, MPH, PhD; Assistant Professor; Rutgers Cancer Institute of New Jersey
Steven J. Bors; Program Manager; NJDOH Vaccine Preventable Disease Program

Acknowledgment: This project was funded by Rutgers School of Nursing

By Gender

By Age Group

Receiving of One Dose of HPV Vaccine in New Jersey
For All Adolescents, by Gender, and by Age Group

2010-2013 2014-2017

% receiving dose

0% 10% 20% 30% 40% 50% 60% 70% 80%

ALL Females Males 11-13 years old 14-16 years old 17-19 years old
Healthcare Providers’ Recommendation of HPV Vaccination in New Jersey

Based on an online survey of 389 HCPs

Rula Btoush, PhD, RN; Associate Professor; Rutgers School of Nursing
Dennis P. Carmody, PhD; Professor Emeritus; Rutgers School of Nursing
Jennifer Tsui, MPH, PhD; Assistant Professor; Rutgers Cancer Institute of New Jersey
Shawna Hudson, PhD; Professor; Rutgers Robert Wood Johnson Medical School

Acknowledgment: This project was funded by Rutgers Cancer Institute of New Jersey
Methods

- Online survey of 389 HCPs in New Jersey
- Survey questions on:
  - HCP recommendation of the HPV vaccine
  - Knowledge and beliefs about the vaccine
  - Barriers (parent-related and system-related barriers)
  - Cues to action (facilitators) for recommending the HPV vaccine
- Email announcements via VFC program, NJAAP, APN-NJ, and other collaborators and through word of mouth

Who was included in the survey?

<table>
<thead>
<tr>
<th>Healthcare providers [HCPs] characteristics</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>28%</td>
</tr>
<tr>
<td>Female</td>
<td>72%</td>
</tr>
<tr>
<td>Clinical Specialty</td>
<td></td>
</tr>
<tr>
<td>Pediatrics</td>
<td>62%</td>
</tr>
<tr>
<td>Women’s Health or OB/GYN</td>
<td>18%</td>
</tr>
<tr>
<td>Family Medicine/Family Health</td>
<td>20%</td>
</tr>
<tr>
<td>Profession</td>
<td></td>
</tr>
<tr>
<td>Physician</td>
<td>75%</td>
</tr>
<tr>
<td>Nurse Practitioner</td>
<td>25%</td>
</tr>
<tr>
<td>Practice Type</td>
<td></td>
</tr>
<tr>
<td>Private Practice</td>
<td>58%</td>
</tr>
<tr>
<td>Public Clinic</td>
<td>18%</td>
</tr>
<tr>
<td>FQHC</td>
<td>13%</td>
</tr>
<tr>
<td>Other</td>
<td>13%</td>
</tr>
</tbody>
</table>

Rates of HCPs “Always” Recommending HPV Vaccine (>75% of the time)
Factors with Significant Influence on HCP’s Recommendation of HPV Vaccination

- Higher rates of HCPs recommending HPV vaccination among:
  - Pediatric vs. non-pediatric providers (81% vs. 55%)
  - Higher levels of knowledge
  - Lower levels of concerns about the HPV vaccine
  - Lower levels of system-related barriers
  - Higher levels of cues to action (facilitators)

More on HCPs’ Reported Knowledge, Concerns, System-Related Barriers, and Facilitators

- Knowledge about the HPV vaccine
  - Generally high levels of knowledge about indications and recommendations related to age, gender, and dosing intervals
  - Lower levels of knowledge about side effects and recommendations regarding catchup doses
- Concerns about the HPV vaccine
  - Vaccine safety, it being pushed by drug companies to make money, and long-term effects
- System-related barriers
  - Reimbursement issues for the vaccine or administration of the vaccine, difficulty ordering enough stock of the vaccine, and inadequate support staff to administer the HPV vaccine
- Facilitators
  - Awareness of CDC and professional organizations’ recommendations for the HPV vaccine
  - Valuing the importance to adhere to these recommendations
  - Having regular staff meetings to present and discuss performance data on vaccination and other quality indicators
Thank you!

For more information:
Rula.Btouh@Rutgers.edu